Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)
NCT05922995 · Brigham and Women's Hospital · EARLY_PHASE1 · terminated · last registry update 2025-10-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study will not longer be done. Terminated due to sponsor noncompliance.” | – | Registry record, Brigham and Women's Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTNR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-08Phase 3 first posted: Menoufia University, Melatonin + Placebo (NCT07865988)
- 2026-09-09Results posted on the registry: Neurim Pharmaceuticals Ltd., Piromelatine 20 mg + Placebo (NCT05267535)
- 2026-09-09Also stopped (terminated): Neurim Pharmaceuticals Ltd., Piromelatine 20 mg + Placebo (NCT05267535)
- 2026-08-21Results posted on the registry: University of Cincinnati, a drug against MTNR1A (NCT04724668)
- 2026-07-23Phase 3 first posted: Ain Shams University, Melatonin (NCT07721324)
- 2026-06-17Phase 3 first posted: University of Child Health Sciences and Children's Hospital, Lahore, MgSO4 (seizure prevention) + Melatonin , Mgso4 (NCT07652801)
- 2026-05-08Phase 3 first posted: Assistance Publique Hopitaux De Marseille, Pediatric Prolonged-Released Melatonin (PedPRM) + Placebo (NCT07576764)
- 2026-03-31Phase 3 first posted: Ain Shams University, Melatonin (NCT07503600)
- 2026-02-20Also stopped (terminated): Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Melatonin (NCT03540485)
- 2026-02-18Phase 3 first posted: University Hospital, Strasbourg, France, pediatric, prolonged released melatonin + Placebo (NCT07418554)
- 2026-02-12Results posted on the registry: Brigham and Women's Hospital, placebo (NCT02642640)
- 2026-02-04Results posted on the registry: M.D. Anderson Cancer Center, Methylphenidate Hydrochloride + Therapeutic Melatonin (NCT01628029)
- 2026-01-13Phase 3 first posted: Emory University, Zolpidem (NCT07336277)
- 2026-01-13Phase 3 first posted: Ain Shams University, Melatonin group + Midazolam group (NCT07336095)
- 2025-12-24Also stopped (withdrawn): University of Colorado, Denver, a drug against MTNR1A (NCT06292000)
- 2025-10-14Results posted on the registry: Brigham and Women's Hospital, a drug against MTNR1A (NCT04868539)
- 2025-08-29Results posted on the registry: National Taiwan University Hospital, Melatonin + Placebo (NCT05439876)
- 2025-08-20Results posted on the registry: Oregon Health and Science University, melatonin (NCT04932096)
- 2025-08-13Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, a drug against MTNR1A (NCT07120880)
- 2025-05-04Results posted on the registry: NYU Langone Health, Melatonin 5 mg (NCT04795336)
- 2025-05-01Phase 3 first posted: Vanda Pharmaceuticals, Tasimelteon Oral Suspension + Placebo (NCT06953869)
- 2025-04-20Phase 3 first posted: Tanta University, Dexmedetomidine + Melatonin (NCT06935292)
- 2025-04-11Also stopped (withdrawn): Stanford University, Melatonin 5 mg + Placebo Oral Tablet (NCT03879707)
- 2025-03-05Phase 3 first posted: Bart Koes, Melatonin 10 mg + Placebo (NCT06859957)
- 2025-02-27Results posted on the registry: Providence Health & Services, 3 mg Melatonin + 5 mg Melatonin (NCT03498131)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision